Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications

• 발행기관: 한국역학회
• 저자명: Aliabbas A. Husain Andreas Kupz Rajpal S. Kashyap
• 간행물 정보: 『Epidemiology and Health』43, 1~9쪽, 전체 9쪽
• 주제분류: 의약학 > 면역학
• 파일형태: PDF
• 발행일자: 2021.01.01

영문 초록

India has a higher tuberculosis (TB) burden than any other country, accounting for an estimated one-fourth of the global burden. Drug-resistant tuberculosis (DR-TB) presents a major public health problem in India. Patients with DR-TB often require profound changes in their drug regimens, which are invariably linked to poor treatment adherence and sub-optimal treatment outcomes compared to drug-sensitive TB. The challenge of addressing DR-TB is critical for India, as India contributes over 27% of global DR-TB cases. In recent decades, India has been proactive in its battle against TB, even implementing a revised National Strategic Plan to eliminate TB by 2025. However, to achieve this ambitious goal, the country will need to take a multifaceted approach with respect to its management of DR-TB. Despite concerted efforts made by the National TB Elimination Program, India faces substantial challenges with regard to DR-TB care, especially in peripheral and resource-limited endemic zones. This article describes some of the major challenges associated with mitigating the growing DR-TB epidemic in India and their implications.

목차

INTRODUCTION

LOW RATE OF CASE NOTIFICATION AND LACK OF QUALITY PATIENT CARE IN THE PRIVATE SECTOR

LIMITED DIAGNOSTIC CAPACITY FOR DR-TB IN PERIPHERAL AND RESOURCE-LIMITED REGIONS OF INDIA

CHALLENGES ASSOCIATED WITH TREATMENT ADHERENCE AND DISSEMINATION OF NEW TREATMENT GUIDELINES OF MDR-TB AMONG HEALTH PROVIDERS

LACK OF STUDIES ON MOLECULAR EPIDEMIOLOGY AND TRANSMISSION DYNAMICS FOR MDR-TB IN HIGH ENDEMIC REGIONS

CONCLUSION

CONFLICT OF INTEREST

FUNDING

ACKNOWLEDGEMENTS

AUTHOR CONTRIBUTIONS

ORCID

REFERENCES

키워드

Tuberculosis India, Drug resistance Diagnosis Epidemics